Tumor Mutation Score Is More Powerful Than Tumor Mutation Burden in Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer

被引：0
|
作者：
Li, Y. [1 ]
Chen, Z. [2 ]
Wu, L. [1 ]
Tao, W. [1 ]
机构：
[1] Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Tumor Mutation Score; Tumor Mutation Burden; PD-L1;
D O I：
10.1016/j.jtho.2019.08.1545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-40
引用
收藏
页码：S724 / S724
页数：1
相关论文
共 50 条
  • [31] Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis
    Zhao, Jie
    Dong, Yiting
    Bai, Hua
    Duan, Jianchun
    Wang, Guoqiang
    Xu, Jiachen
    Wang, Jie
    Wang, Zhijie
    JOURNAL OF THE NATIONAL CANCER CENTER, 2022, 2 (01): : 41 - 49
  • [32] Immunotherapy for non-small cell lung cancer
    Kagamu, Hiroshi
    RESPIRATORY INVESTIGATION, 2024, 62 (02) : 307 - 312
  • [33] Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy
    Patel, Shetal A.
    Weiss, Jared
    CLINICS IN CHEST MEDICINE, 2020, 41 (02) : 237 - +
  • [34] Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immuno-checkpoint inhibitors for non-small cell lung cancer (NSCLC)
    Ma, Xiaoting
    Zhang, Yujian
    Wang, Shan
    Yu, Jing
    JOURNAL OF CANCER, 2021, 12 (02): : 584 - 594
  • [35] Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden
    van den Heuvel, Guus R. M.
    Kroeze, Leonie I.
    Ligtenberg, Marjolijn J. L.
    Grunberg, Katrien
    Jansen, Erik A. M.
    von Rhein, Daniel
    de Voer, Richarda M.
    van den Heuvel, Michel M.
    RESPIRATORY RESEARCH, 2021, 22 (01)
  • [36] Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient
    Fu, Yang
    Zheng, Yue
    Wang, Pei-Pei
    Chen, Yue-Yun
    Ding, Zhen-Yu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [37] Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden
    Naito, Tomoyuki
    Udagawa, Hibiki
    Umemura, Shigeki
    Sakai, Tetsuya
    Zenke, Yoshitaka
    Kirita, Keisuke
    Matsumoto, Shingo
    Yoh, Kiyotaka
    Niho, Seiji
    Tsuboi, Masahiro
    Ishii, Genichiro
    Goto, Koichi
    LUNG CANCER, 2019, 138 : 35 - 42
  • [38] Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Isomoto, Kohsuke
    Haratani, Koji
    Hayashi, Hidetoshi
    Shimizu, Shigeki
    Tomida, Shuta
    Niwa, Takashi
    Yokoyama, Toshihide
    Fukuda, Yasushi
    Chiba, Yasutaka
    Kato, Ryoji
    Tanizaki, Junko
    Tanaka, Kaoru
    Takeda, Masayuki
    Ogura, Takashi
    Ishida, Tadashi
    Ito, Akihiko
    Nakagawa, Kazuhiko
    CLINICAL CANCER RESEARCH, 2020, 26 (08) : 2037 - 2046
  • [39] Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer
    Ozaki, Yuki
    Muto, Satoshi
    Takagi, Hironori
    Watanabe, Masayuki
    Inoue, Takuya
    Fukuhara, Mitsuro
    Yamaura, Takumi
    Okabe, Naoyuki
    Matsumura, Yuki
    Hasegawa, Takeo
    Ohsugi, Jun
    Hoshino, Mika
    Shio, Yutaka
    Tanaka, Daisuke
    Nanamiya, Hideaki
    Imai, Jun-ichi
    Isogai, Takao
    Watanabe, Shinya
    Suzuki, Hiroyuki
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (01) : 127 - 134
  • [40] Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer
    Yuki Ozaki
    Satoshi Muto
    Hironori Takagi
    Masayuki Watanabe
    Takuya Inoue
    Mitsuro Fukuhara
    Takumi Yamaura
    Naoyuki Okabe
    Yuki Matsumura
    Takeo Hasegawa
    Jun Ohsugi
    Mika Hoshino
    Yutaka Shio
    Daisuke Tanaka
    Hideaki Nanamiya
    Jun-ichi Imai
    Takao Isogai
    Shinya Watanabe
    Hiroyuki Suzuki
    Cancer Immunology, Immunotherapy, 2020, 69 : 127 - 134
12345